MAPKAPK3 and central nervous system cancer: The survival analyses found that high expression of MK3 was negatively correlated with the OS rate of glioma patients (Figures 3B–D), while survival analyses of histological type for glioma patients showed that MK3 did not affect survival in GBM (Figure 3O), which might be limited by the small number of patients enrolled due to the short survival time and low survival rate of GBM (29).